Protein News and Research

RSS

Proteins are complex molecules that are made up of amino acids. They can be found in every cell in the body, and carry out vital processes that keep human beings alive. Mutations in proteins can lead to a multitude of diseases, the most common being cancer.

Abbott presents data from 4 briakinumab pivotal studies in psoriasis

In four separate pivotal clinical studies presented on Friday, a greater percentage of moderate to severe chronic plaque psoriasis patients treated with briakinumab, Abbott's investigational IL-12/23 inhibitor (ABT-874), achieved 75 percent or better skin clearance rates than those treated with etanercept (Enbrel®), methotrexate or placebo. Abbott presented data from all briakinumab pivotal studies in psoriasis at the European Association of Dermatology and Venereology scientific sessions.

11 Oct 2010

Micromet to initiate MEDI-565 Phase 1 trial in patients with advanced gastrointestinal cancer

Micromet, Inc. today announced that its licensee for MT111, MedImmune, plans to initiate a Phase 1 trial in patients with advanced gastrointestinal cancers based on an investigational new drug (IND) application recently accepted by the U.S. Food and Drug Administration (FDA).

11 Oct 2010

Novel hormonal treatments may help ER-negative breast cancer patients: Study

Women who have estrogen (ER) negative breast cancer may have more drug treatment options than previously thought, a Creighton (pronounced Cray-ton) University study suggests. The study is reported in the Oct. 11 online version of the journal Oncogene.

11 Oct 2010

Combination of MET and erlotinib delays lung cancer progression: Study

A subset of lung cancer patients seem to live longer and experience delays in disease progression when a new drug that targets a cancer-associated molecule called MET is added to treatment with erlotinib, the results of a double-blind Phase-II trial show.

11 Oct 2010

Promising clinical data of ImmunoGen's lorvotuzumab mertansine to be presented at ESMO conference

ImmunoGen, Inc., a biopharmaceutical company that develops targeted anticancer therapeutics using its Targeted Antibody Payload (TAP) technology, today announced the presentation of encouraging clinical data for the Company's lorvotuzumab mertansine (IMGN901) targeted anticancer compound at the 35th European Society for Medical Oncology (ESMO) Conference being held in Milan, Italy, October 8-12, 2010.

11 Oct 2010

Study to uncover genetic basis of obesity

An international consortium has made significant inroads into uncovering the genetic basis of obesity by identifying 18 new gene sites associated with overall obesity and 13 that affect fat distribution. The studies include data from nearly a quarter of a million participants, the largest genetic investigation of human traits to date.

11 Oct 2010

New experimental vaccine against Alzheimer's disease

Researchers at UT Southwestern Medical Center have created an experimental vaccine against beta-amyloid, the small protein that forms plaques in the brain and is believed to contribute to the development of Alzheimer's disease.

11 Oct 2010

Exelixis enters two new collaboration agreements with Bristol-Myers Squibb

Exelixis, Inc. announced today that it has entered into two new collaboration agreements with Bristol-Myers Squibb Company. Under the first agreement, Exelixis will grant to Bristol-Myers Squibb an exclusive license to its small-molecule TGR5 agonist program including backups.

11 Oct 2010

'Achilles heel' for HCV infection

Scientists at the Gladstone Institute of Virology and Immunology (GIVI) have found that an enzyme associated with the storage of fat in the liver is required for the infectious activity of the hepatitis C virus (HCV). This discovery may offer a new strategy for treating the infection.

11 Oct 2010

Scientists proves Yersinia pestis as causative agent for Black Death epidemics in European continent

The latest tests conducted by anthropologists at the Johannes Gutenberg University Mainz (JGU) have proven that the bacteria Yersinia pestis was indeed the causative agent behind the "Black Death" that raged across Europe in the Middle Ages. The cause of the epidemic has always remained highly controversial and other pathogens were often named as possible causes, in particular for the northern European regions.

11 Oct 2010

Takeda, Envoy enter three-year research alliance to develop schizophrenia drug

Takeda Pharmaceutical Company Limited, a global pharmaceutical company, and Envoy Therapeutics Inc., a recently formed drug discovery company, today announced that they have formed a three-year research alliance aimed at discovering drugs for schizophrenia that will have greater efficacy and safety compared to current therapies.

11 Oct 2010

Researchers create experimental vaccine for Alzheimer's disease

11 Oct 2010

Scientists identify molecular mechanism of muscle stem cell differentiation

Under normal circumstances, adult stem cells reside in muscle tissue, where they can differentiate into a number of different cell types. After an injury (or even a tough workout), muscles are inflamed as cells and molecules flood the area to control damage and begin repairs. When called upon to replace muscle tissue damaged by injury or genetic disease, some muscle stem cells differentiate, becoming new muscle cells, while others make more stem cells. At Sanford-Burnham Medical Research Institute (Sanford-Burnham), a team of scientists led by Pier Lorenzo Puri, M.D., Ph.D., recently uncovered the molecular messengers that translate inflammatory signals into the genetic changes that tell muscle stem cells to differentiate.

11 Oct 2010

Research may offer new therapy targets for drug-resistant breast tumors

Researchers at the University of Illinois at Chicago College of Medicine have found how gene expression that may contribute to drug resistance is ramped up in unusual types of breast tumors. Their findings may offer new therapy targets.

11 Oct 2010

Anti-HER2 antibody-drug conjugate effective as first-line therapy for advanced breast cancer: Research

A new type of breast cancer treatment has shown encouraging activity as a first-line therapy in HER2-positive metastatic disease, researchers reported at the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan, Italy.

11 Oct 2010

Biologists determine three-dimensional structure of molecule involved in HIV, cancer

In a technical tour de force, structural biologists funded by the National Institutes of Health have determined the three-dimensional structure of a molecule involved in HIV infection and in many forms of cancer. The high-resolution structure sheds light on how the molecule functions and could point to ways to control its activity, potentially locking out HIV and stalling cancer's spread.

8 Oct 2010

Low-fat diet reduces risk of heart disease

Losing weight, especially among adults who are very heavy to obese, is a good way to prevent the onset of atherosclerosis, the artery-thickening condition that leads to potentially deadly heart disease. A diet that is low in either fats or carbohydrates can help reduce weight. But which one is the more heart-healthy?

8 Oct 2010

Researchers identify molecular mechanism that regulate metastasis of melanoma cells

The way melanoma cells use the immune system to spread and develop into lung tumors may lead to a therapy to decrease development of these tumors, according to Penn State researchers.

8 Oct 2010

NIAID announces three new contracts to fund research on dengue, anthrax vaccines

The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, today announced three new contracts to fund research on vaccines to protect against emerging infectious diseases and biological threats that could be used in a terror attack. Each project focuses on simple and efficient vaccine delivery approaches that could be deployed quickly. The total funding for the three contracts could reach $68 million, depending on the successful completion of defined project milestones.

8 Oct 2010

Matchmaker function may help cardiologists understand the natural repair process after heart attacks

Heart muscle cells do not normally replicate in adult tissue, but multiply with abandoned during development. This is why the loss of heart muscle after a heart attack is so dire-you can't grow enough new heart muscle to make up for the loss.

8 Oct 2010

Protein News and Research

Further Reading

Abbott presents data from 4 briakinumab pivotal studies in psoriasis

Micromet to initiate MEDI-565 Phase 1 trial in patients with advanced gastrointestinal cancer

Novel hormonal treatments may help ER-negative breast cancer patients: Study

Combination of MET and erlotinib delays lung cancer progression: Study

Promising clinical data of ImmunoGen's lorvotuzumab mertansine to be presented at ESMO conference

Study to uncover genetic basis of obesity

New experimental vaccine against Alzheimer's disease

Exelixis enters two new collaboration agreements with Bristol-Myers Squibb

'Achilles heel' for HCV infection

Scientists proves Yersinia pestis as causative agent for Black Death epidemics in European continent

Takeda, Envoy enter three-year research alliance to develop schizophrenia drug

Researchers create experimental vaccine for Alzheimer's disease

Scientists identify molecular mechanism of muscle stem cell differentiation

Research may offer new therapy targets for drug-resistant breast tumors

Anti-HER2 antibody-drug conjugate effective as first-line therapy for advanced breast cancer: Research

Biologists determine three-dimensional structure of molecule involved in HIV, cancer

Low-fat diet reduces risk of heart disease

Researchers identify molecular mechanism that regulate metastasis of melanoma cells

NIAID announces three new contracts to fund research on dengue, anthrax vaccines

Matchmaker function may help cardiologists understand the natural repair process after heart attacks

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest Life Science News